Abbott’s $870M Volume Slides to 115th Rank as Regulatory Delays and Litigation Weigh, Yet Institutional Buyers Bolster Holdings

Abbott Laboratories (ABT) fell 1.24% on August 13, 2025, with a trading volume of $870 million, ranking 115th in the market by liquidity. The decline came amid mixed signals from recent earnings reports and regulatory developments in key markets. While the company reaffirmed its long-term guidance for its diabetes care and diagnostics segments, short-term volatility persisted due to ongoing patent litigation concerns in the cardiovascular device division.

Analysts noted that the stock's performance was influenced by a regulatory delay in the approval of a next-generation glucose monitoring system in Europe. This setback, combined with elevated cash burn in R&D for oncology pipelines, raised questions about near-term margin stability. However, institutional buying activity remained strong, with three major asset managers increasing their stakes in the stock during the second quarter.

The backtested trading strategy of purchasing the top 500 volume-driven stocks daily and holding for one day yielded a compound annual growth rate of 6.98% from 2022 to 2025. The approach experienced a maximum drawdown of 15.59% in mid-2023 but maintained steady growth thereafter. These results suggest high-volume strategies can generate consistent returns when paired with disciplined risk management protocols.